KROS logo

KROS
Keros Therapeutics Inc

1,234
Mkt Cap
$230.1M
Volume
225,794.00
52W High
$22.55
52W Low
$10.42
PE Ratio
6.40
KROS Fundamentals
Price
$11.66
Prev Close
$11.67
Open
$11.72
50D MA
$13.00
Beta
0.87
Avg. Volume
573,032.21
EPS (Annual)
$2.30
P/B
0.75
Rev/Employee
$3.13M
$500.28
Loading...
Loading...
News
all
press releases
KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment
Keros heads into 2026 with three key catalysts, including DMD study start, ALS regulatory talks, and Takeda progress, that could reshape investor sentiment.
Zacks·17h ago
News Placeholder
More News
News Placeholder
KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026?
Keros reshaped its finances with a Takeda deal, boosting revenue and cutting R&D ??? but does it truly reduce dilution risk as 2026 uncertainty looms?
Zacks·17h ago
News Placeholder
KROS Rinvatercept: What to Know Before DMD Phase II Starts
KROS sharpens focus on rinvatercept as a phase II DMD study looms in 2026, shifting the story toward execution and high-stakes clinical catalysts.
Zacks·17h ago
News Placeholder
Keros Therapeutics (NASDAQ:KROS) Director Purchases $11,700.00 in Stock
Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) Director Jean Jacques Bienaime acquired 1,000 shares of Keros Therapeutics stock in a transaction dated Wednesday, April 15th. The stock was...
MarketBeat·3d ago
News Placeholder
Keros Therapeutics (NASDAQ:KROS) Director Acquires $11,700.00 in Stock
Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) Director Jean Jacques Bienaime bought 1,000 shares of the firm's stock in a transaction dated Wednesday, April 15th. The stock was acquired at...
MarketBeat·3d ago
News Placeholder
Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Down 24.9% in March
Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) was the recipient of a large decrease in short interest in March. As of March 31st, there was short interest totaling 1,494,814 shares, a...
MarketBeat·5d ago
News Placeholder
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Rating of "Hold" from Analysts
Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) has been assigned a consensus recommendation of "Hold" from the ten analysts that are presently covering the stock, Marketbeat Ratings...
MarketBeat·14d ago
News Placeholder
Keros Therapeutics, Inc. $KROS Shares Acquired by SG Americas Securities LLC
SG Americas Securities LLC lifted its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 1,420.6% in the fourth quarter, according to its most recent Form 13F filing with the...
MarketBeat·15d ago
News Placeholder
JPMorgan Chase & Co. Raises Position in Keros Therapeutics, Inc. $KROS
JPMorgan Chase & Co. grew its position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 260.8% during the third quarter, according to the company in its most recent disclosure...
MarketBeat·15d ago
News Placeholder
Why Is Keros Therapeutics (KROS) Up 2.5% Since Last Earnings Report?
Keros Therapeutics (KROS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·18d ago
<
1
2
...
>

Latest KROS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.